TREATMENT METHOD
Methods of treating and/or preventing a cardiovascular disease in a human suffering from an allergic and/or inflammatory condition or cardiovascular disease by administrating an effective amount of loratadine, in combination with an effective amount of montelukast, for such treating and/or preventing are disclosed.
1 . A method of treating cardiovascular disease in a human suffering from an allergic and/or inflammatory condition which comprises administering to such human in need of such treating an effective amount of loratadine, or a pharmaceutically acceptable salt thereof, in combination with an effective amount of montelukast, or a pharmaceutically acceptable salt thereof.
2 . The method of claim 1 , wherein the effective amount of loratadine is about 1 mg/day to about 45 mg/day.
3 . The method of claim 2 , wherein the effective amount of loratadine is about 5 mg/day to about 15 mg/day.
4 . The method of claim 3 , wherein the effective amount of loratadine is about 5 mg/day to about 10 mg/day.
5 . The method of claim 4 , wherein the effective amount of loratadine is about 10 mg/day.
6 . The method of claim 1 , wherein the allergic and/or inflammatory is seasonal allergic rhinitis, perennial allergic rhinitis, atopic dermatitis, urticaria or allergic asthma.
7 . The method of claim 1 , wherein the effective amount of montelukast is about 5 mg/day to about 20 mg/day.
8 . The method of claim 7 , wherein the effective amount of montelukast is about 10 mg/day.
9 . A method of treating cardiovascular disease in a human in need of such treating which comprises administering to such human in need of such treating and/or preventing an effective amount of loratadine, or a pharmaceutically acceptable salt thereof, in combination with an effective amount of montelukast, or a pharmaceutically acceptable salt thereof.
10 . The method of claim 9 , wherein the effective amount of loratadine is in the range of about 1 mg/day to about 45 mg/day.
11 . The method of claim 10 , wherein the effective amount of loratadine is about 5 mg/day to about 15 mg/day.
12 . The method of claim 11 , wherein the effective amount of loratadine is about 5 mg/day to about 10 mg/day.
13 . The method of claim 12 , wherein the effective amount of loratadine is about 10 mg/day.
14 . The method of claim 9 , wherein the effective amount of montelukast is about 5 mg/day to about 20 mg/day.
15 . The method of claim 14 , wherein the effective amount of montelukast is about 10 mg/day.
16 . A method of treating cardiovascular disease in a human suffering from seasonal or perennial allergic rhinitis which comprises administering to such human in need of such treating an effective amount of loratadine, or a pharmaceutically acceptable salt thereof, in combination with an effective amount of montelukast, or a pharmaceutically acceptable salt thereof.
17 . The method of claim 16 , wherein the effective amount of loratadine is about 1 mg/day to about 45 mg/day.
18 . The method of claim 17 , wherein the effective amount of loratadine is about 5 mg/day to about 15 mg/day.
19 . The method of claim 18 , wherein the effective amount of loratadine is about 5 mg/day to about 10 mg/day.
20 . The method of claim 19 , wherein the effective amount of loratadine is about 10 mg/day.
21 - 35 . (canceled)